Capnomed GmbH stands at the forefront of medical innovation, specializing in medical devices and pharmaceutical drug development for oncology. Headquartered in Germany, the company has established itself as a global supplier of cutting-edge cancer treatment solutions. Its flagship technology, Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC), administered via the patented CapnoPen®, is revolutionizing cancer care by offering a more targeted, less invasive, and better-tolerated treatment alternative for patients worldwide.
Innovative Solutions for Cancer Treatment
Traditional chemotherapy and radiation treatments often come with severe side effects, high costs, and limited success rates, particularly for advanced peritoneal cancers. Capnomed addresses these challenges through its CapnoPen®, a single-use device designed for precise, localized administration of anticancer drugs. By controlling drop size, spray angles, and flow rates, this breakthrough technology enhances drug absorption while minimizing systemic toxicity, leading to improved patient outcomes.
PIPAC treatment is particularly beneficial for individuals suffering from advanced gastric, colorectal, and ovarian cancers that have spread to the peritoneum. The procedure allows for a quick, safe, and effective administration of chemotherapy directly at the cancer site, resulting in significantly fewer side effects compared to standard chemotherapy methods.
Bridging Scientific Excellence Between East and West
With a presence in over 45 countries and nearly 10,000 successful medical applications, Capnomed is rapidly expanding into new markets. Recognizing the urgent need for innovative cancer treatment in Asia and the Middle East, the company is strategically growing its presence in countries such as Singapore, India, China, Malaysia, South Korea, Thailand, and the Philippines.
Singapore was the first country in Asia to adopt PIPAC through clinical trials, led by Prof. Jimmy So from the National University of Singapore, who emphasizes the pressing need for more effective chemotherapy delivery methods. Capnomed is committed to working alongside leading medical institutions across the region to facilitate research, regulatory approvals, and the widespread adoption of its technology.
Commitment to Innovation and Patient Well-Being
At the core of Capnomed’s success is a multidisciplinary team of engineers, pharmaceutical scientists, and regulatory experts dedicated to advancing medical aerosol technology and drug delivery systems. The company’s focus on continuous research and development ensures that its products evolve to meet the changing demands of modern cancer treatment.
Capnomed’s mission extends beyond technological innovation—it is about restoring hope to cancer patients by offering minimally invasive, well-tolerated, and more effective treatment options. The company acknowledges that the fight against cancer is an ongoing challenge, but remains unwavering in its commitment to delivering high-quality solutions that improve patients’ quality of life.
Shaping the Future of Oncology
Capnomed’s groundbreaking work in oncology reflects a deep understanding of both the scientific complexities of cancer and the human impact of the disease. By merging cutting-edge technology with compassionate patient care, the company is redefining the landscape of cancer treatment.
As it continues to expand across continents, Capnomed remains steadfast in its pursuit of a superior treatment plan, ensuring that cancer patients around the world have access to innovative, life-changing solutions.
Capnomed has humanized the face of the cancer patient and is pulling out all stops in search of a superior treatment plan for the disease.
